Samsung Biologics to join carbon neutral initiative

By The Science Advisory Board staff writers

September 13, 2021 -- Contract development and manufacturing organization Samsung Biologics has signed a memorandum of understanding to join the Frontier 1.5D initiative, which will develop a climate risk management model as part of South Korea's 2050 Carbon Neutral Strategy.

Samsung Biologics has joined the Frontier 1.5D Project as part of the 2050 Carbon Neutral Initiative. Image courtesy of Samsung Biologics.

Frontier 1.5D is an effort to limit global temperature rise to 1.5 degrees Celsius above preindustrial levels. Samsung plans to monitor its biopharmaceutical manufacturing plants through an initiative it calls the Carbon Disclosure Project, the company said.

Samsung Biologics reports growth in Q2
New contracts and increased plant utilization propelled Samsung Biologics to a 34% increase in revenue in its second quarter.
Kineta, Samsung Biologics partner on solid-tumor therapy
Samsung Biologics has inked a deal providing end-to-end development and manufacturing services to advance Kineta's anti-V-domain immunoglobulin suppressor...
Samsung Biologics readies mRNA vaccine drug substance production
Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.
Samsung Biologics breaks ground on 'super plant'
Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.
Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter